Item 7.01 Regulation FD.



On March 14, 2022, AnaptysBio, Inc. issued a press release announcing
imsidolimab ACORN Phase 2 clinical trial data in moderate-to-severe acne. A copy
of the press release is attached as Exhibit 99.1 to this report and incorporated
herein by reference.

The information within this report, including Exhibit 99.1 to this Current
Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this report and in the
accompanying Exhibit 99.1 shall not be incorporated by reference into any
registration statement or other document filed by AnaptysBio with the Securities
and Exchange Commission, whether made before or after the date of this Current
Report on Form 8-K, regardless of any general incorporation language in such
filing (or any reference to this Current Report on Form 8-K generally), except
as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits



Exhibit Number               Exhibit Title or Description
  99.1                       Press release issued by AnaptysBio, Inc.

regarding imsidolimab ACORN Phase


                             2 clinical trial data in moderate-to-severe acne, dated March 14, 2022.
104                          Cover Page Interactive Data File (the cover

page XBRL tags are embedded


                             within the inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses